XML 36 R25.htm IDEA: XBRL DOCUMENT v3.24.3
Commitments and Contingencies (Tables)
 9 Months Ended
Sep. 30, 2024
Commitments and Contingencies Disclosure [Abstract]  
Schedule of Contractual Clinical Trials

The following is a summary of the Company’s ongoing contractual clinical trials described below as of September 30, 2024:

 

Description of Clinical Trial  Institution  Start Date  Projected End Date 

Number of Patients

in Trial

  Study Objective  Clinical Update 

Expected

Date of Preliminary Efficacy

Signal

  NCT No. 

Remaining

Financial

Contractual

Commitment

 
                             
LB-100 combined with atezolizumab in microsatellite stable metastatic colon cancer (Phase 1b)  Netherlands Cancer Institute (NKI)  August 2024  December 2026  37  Determine RP2D with atezolizumab  First patient entered August 2024  June 2026  NCT06012734   -   (1)
                              
LB-100 combined with doxorubicin in advanced soft tissue sarcoma (Phase 1b)  GEIS  June 2023  Recruitment completed September 2024  9 to 18  Determine MTD and RP2D  Fourteen patients entered  March 2025  NCT05809830  $284,000 
                              
Doxorubicin with or without LB-100 in advanced soft tissue sarcoma (Randomized Phase 2)  GEIS  TBD  TBD  150  Determine efficacy: PFS  Clinical trial not yet begun (subject to completion of Phase 1b GEIS clinical trial)  December 2026  NCT05809830  $3,332,000 
                              
LB-100 combined with dostarlimab in ovarian clear cell carcinoma (Phase 1b/2)  MD Anderson  January 2024  December 2027  21  Determine the OS of patients with recurrent ovarian clear cell carcinoma  Seven patients entered  December 2026  NCT06065462   -   (1)
                              
Total                          $3,616,000 

 

(1) The Company has no financial contractual commitment associated with this clinical trial at September 30, 2024.